A perspective on how the longevity sector has progressed from a hype-driven startup wave to a more complex, translational, and industry-integrated phase.
Key Takeaways
- Lot of those companies no longer exist; there are disadvantages in being first into a space
- It will be become unremarkable to attempt to treat aging as a medical condition
- Number of such approved drugs is somewhat less important than the collective revenue generated